Search
Meclofenoxate
go.drugbank.com/drugs/DB13758InvestigationalCategories: Compounds used in a research, industrial, or household settingTocopherylquinone
go.drugbank.com/drugs/DB14094InvestigationalSynonyms: Vitamin E quinoneCategories: Compounds used in a research, industrial, or household settingMorin
go.drugbank.com/drugs/DB16770ExperimentalCategories: Compounds used in a research, industrial, or household setting3,4-Dihydroxybenzoic Acid
go.drugbank.com/drugs/DB03946ExperimentalCategories: Compounds used in a research, industrial, or household settingCetilistat
go.drugbank.com/drugs/DB06586InvestigationalCetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
EW-A-401
go.drugbank.com/drugs/DB05525InvestigationalEW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes. … This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels.
Synonyms: EW-A-401 DNA Plasmid VectorGalsulfase
go.drugbank.com/drugs/DB01279ApprovedInvestigationalGalsufase is a variant form of the polymorphic human enzyme N-acetylgalactosamine 4-sulfatase of recombinant DNA origin. Galsulfase is a glycoprotein with a molecular weight of approximately 56 kD. … Post-translational modification of Cys53 produces the catalytic amino acid residue Ca-formylglycine, which is required for enzyme activity and is conserved in all members of the sulfatase enzyme family
Synonyms: N-acetylgalactosamine-4-sulfatase, recombinant humanFX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalSirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. S...